THERAPY DOSSIER · th-9f608d273d3f

Alogliptin benzoate

Drug · Dipeptidyl peptidase IV (DPP-4) inhibitor (INHIBITOR)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Dipeptidyl peptidase IV (DPP-4) inhibitor (INHIBITOR)
Target: CHEMBL284
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: 2013
Development stage: Not recorded
ChEMBL record: CHEMBL227529 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Alogliptin benzoate; Nesina; Vipidia; SYR-322
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02771093 ↗PHASE4completed

Trelagliptin and alogliptin effects on glucose variability by CGM in type 2 diabetes

Type 2 Diabetes Mellitus

Enrolment: 27 · Results not recorded

NCT00707993 ↗PHASE3completed

Alogliptin compared to glipizide in elderly subjects with type 2 diabetes

Diabetes Mellitus

Enrolment: 441 · Results not recorded

NCT01263483 ↗PHASE2/PHASE3completed

SYR-322 (alogliptin) with alpha-glucosidase inhibitor in type 2 diabetes in Japan

Type 2 Diabetes Mellitus

Enrolment: 230 · Results not recorded

NCT01318070 ↗PHASE2/PHASE3completed

SYR-322 (alogliptin) with thiazolidine in type 2 diabetes in Japan

Type 2 Diabetes Mellitus

Enrolment: 339 · Results not recorded

NCT01990300 ↗Phase not recordedcompleted

Long-term use of alogliptin/pioglitazone combination tablets in type 2 diabetes

Type 2 Diabetes Mellitus

Enrolment: 3281 · Results not recorded

NCT02989649 ↗Phase not recordedterminated

Non-interventional study of alogliptin and alogliptin fixed-dose combinations in standard clinical practice

Diabetes Mellitus, Type 2

Enrolment: 593 · Results not recorded

NCT01964976 ↗Phase not recordedcompleted

Nesina (alogliptin) tablets special drug use surveillance: combination therapy with biguanides

Surveillance

Enrolment: 1096 · Results not recorded

NCT01588587 ↗Phase not recordedunknown

Effect of DPP-IV inhibitors (including alogliptin) on occurrence of cancers in type 2 diabetes

Type 2 Diabetes Mellitus

Enrolment: 500 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23602966 ↗2013Mixed findings

Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6JMaleIntragastric gavage7.5, 15 or 30 micrograms per mousePretreatment for three weeks before induction of ischaemia

Model: Temporary focal cerebral ischaemia in non-diabetic mice

The 15 microgram dose significantly reduced infarct volume (p = 0.009) and neurological deficit (p = 0.004) at 24 h, persisting into the chronic phase, while the 7.5 and 30 microgram doses did not; brain-derived neurotrophic factor was elevated in cortex and whole forebrain before ischaemia.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…